Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea

Arancibia, Eva Mendez; Pitart, Cristina; Ruiz, Joaquı́m; Marco, Francesc; Gascón, Joaquím; Vila, Jordi

doi:10.1093/jac/dkp178

Cited by 59 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first report of the occurrence of qnr genes in STEC, aEPEC, and EIEC clinical strains. Our study also confirms the occurrence of qnr genes in EAEC strains reported by Riveros et al (8) and Kim et al (9), which might have contributed to the increasing trend of fluoroquinolone resistance recently observed in this E. coli pathotype worldwide (8,10). As for the plasmids, although qnrB19 has previously been found in ColE-like plasmids (8,11), qnrS1 has rarely been identified in IncK plasmids.…”

supporting

confidence: 91%

Plasmid-Mediated Quinolone Resistance in Different Diarrheagenic Escherichia coli Pathotypes Responsible for Complicated, Noncomplicated, and Traveler's Diarrhea Cases

Herrera-León

Llorente

Sánchez

2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

supporting

confidence: 91%

Plasmid-Mediated Quinolone Resistance in Different Diarrheagenic Escherichia coli Pathotypes Responsible for Complicated, Noncomplicated, and Traveler's Diarrhea Cases

Herrera-León

Llorente

Sánchez

2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…A study looking at the changing antibiotic resistance profiles of ETEC showed that nearly 60% of isolates were resistant to trimethoprim-sulfamethoxazole and tetracycline and approximately 50% to ampicillin for isolates from 2001 to 2004 (764). Of concern is the noted increase of ciprofloxacin resistance from 1% in the period of 1994 to 1997 to 8% in 2001 to 2004, where most of the ciprofloxacin resistant ETEC strains were isolated from patients who traveled to India.…”

Section: Clinical Considerationsmentioning

confidence: 99%

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

et al. 2013

View full text Add to dashboard Cite

SUMMARY Although Escherichia coli can be an innocuous resident of the gastrointestinal tract, it also has the pathogenic capacity to cause significant diarrheal and extraintestinal diseases. Pathogenic variants of E. coli (pathovars or pathotypes) cause much morbidity and mortality worldwide. Consequently, pathogenic E. coli is widely studied in humans, animals, food, and the environment. While there are many common features that these pathotypes employ to colonize the intestinal mucosa and cause disease, the course, onset, and complications vary significantly. Outbreaks are common in developed and developing countries, and they sometimes have fatal consequences. Many of these pathotypes are a major public health concern as they have low infectious doses and are transmitted through ubiquitous mediums, including food and water. The seriousness of pathogenic E. coli is exemplified by dedicated national and international surveillance programs that monitor and track outbreaks; unfortunately, this surveillance is often lacking in developing countries. While not all pathotypes carry the same public health profile, they all carry an enormous potential to cause disease and continue to present challenges to human health. This comprehensive review highlights recent advances in our understanding of the intestinal pathotypes of E. coli .

show abstract

“…As a consequence, quinolones became the drugs of choice for traveller's diarrhea but resistance to these drugs has also emerged. As with other E. coli, this is typically due to point mutations in the quinolone resistance determining regions of the gyrA and parC genes although other, more recently described, mechanisms are yet to be investigated [118,119].…”

Section: Enteropathogenic E Colimentioning

confidence: 99%

“…Due to resistance, quinolones have replaced doxycycline and trimethoprim-sulphamethoxazole as drugs of choice for travellers diarrhea, but quinolone resistance has since emerged and is increasing. The only promising alternative is rifaximin, a recently licensed, non-absorbable antimicrobial that can be used to treat infections by non-invasive E. coli pathotypes [85,119,[270][271][272][273]. Availability and costs mean that rifamixin is presently limited to adjusting recommendations for travellers from affluent countries to compensate for the emergence of resistance, a niche occupied until now by ciprofloxacin.…”

Section: Clinically Relevant Unanswered Questions About the Biology Omentioning

confidence: 99%

Diarrheagenic Escherichia coli in sub-Saharan Africa: Status, Uncertainties and Necessities

Okeke

2009

J Infect Dev Ctries

120

103

View full text Add to dashboard Cite

Diarrhea is a leading cause of illness and death, particularly in developing countries. Enteropathogenic Escherichia coli, enterotoxigenic E. coli (ETEC), enteroinvasive E. coli, enterohemorrhaghic E. coli (EHEC), enteroaggregative E. coli (EAEC) and diffusely adherent E. coli (DAEC) have been associated with diarrheal disease in different parts of Africa, particularly among young children, HIV-positive individuals, and visitors from abroad. Each of these E. coli pathotypes uses distinct mechanisms, which are only partially understood, to colonize infected hosts and produce diarrhea. All known diarrheagenic E. coli pathotypes have been reported from diverse locations within Africa but the true burden from these pathogens is unknown because very few studies seeking these organisms with discriminatory methodology have been performed. Recent reports implicate ETEC and EAEC in a considerable proportion of childhood and travellers' diarrheas and suggest that some sub-types of these categories may have greater epidemiological significance than others. The significant contribution of EHEC to bloody diarrhea and hemolytic uremic syndrome is underappreciated because diagnostic capacity for this pathotype is generally inferior to that for confounders such as Shigella and Entamoeba. Recent studies in Africa have revealed the worrisome emergence of antimicrobial resistance and high asymptomatic carriage rates for diarrheagenic E. coli but bacterial and host factors that predispose to disease, as well as non-human reservoirs, are largely unknown. Future diarrheal disease research needs to focus on broadening the repertoire of pathogens sought in epidemiological surveys to include multiple categories of diarrheagenic E. coli while building capacity to detect these pathogens in local reference laboratories.

show abstract

Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea

Abstract: The high percentage of resistance to quinolones in ETEC and EAEC isolated from travellers to North Africa and India is a matter for concern. These agents should therefore be used with caution in patients with traveller's diarrhoea returning from these geographical areas.

Cited by 59 publications

References 16 publications

Plasmid-Mediated Quinolone Resistance in Different Diarrheagenic Escherichia coli Pathotypes Responsible for Complicated, Noncomplicated, and Traveler's Diarrhea Cases

Plasmid-Mediated Quinolone Resistance in Different Diarrheagenic Escherichia coli Pathotypes Responsible for Complicated, Noncomplicated, and Traveler's Diarrhea Cases

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

Diarrheagenic Escherichia coli in sub-Saharan Africa: Status, Uncertainties and Necessities

Contact Info

Product

Resources

About